Roivant Sciences Ltd. (NASDAQ:ROIV) Major Shareholder Pharma Technologies Ltd Dexcel Acquires 4,000,000 Shares of Stock

Roivant Sciences Ltd. (NASDAQ:ROIVGet Rating) major shareholder Pharma Technologies Ltd Dexcel bought 4,000,000 shares of the stock in a transaction dated Thursday, November 10th. The shares were bought at an average cost of $5.00 per share, with a total value of $20,000,000.00. Following the completion of the acquisition, the insider now directly owns 102,849,443 shares of the company’s stock, valued at approximately $514,247,215. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Large shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.

Roivant Sciences Stock Performance

ROIV opened at $5.29 on Tuesday. The company has a market capitalization of $3.72 billion, a price-to-earnings ratio of -3.31 and a beta of 1.89. The company has a debt-to-equity ratio of 0.22, a current ratio of 6.20 and a quick ratio of 6.20. Roivant Sciences Ltd. has a 1-year low of $2.52 and a 1-year high of $16.76. The business has a 50 day moving average price of $4.20 and a two-hundred day moving average price of $4.08.

Roivant Sciences (NASDAQ:ROIVGet Rating) last announced its quarterly earnings data on Monday, August 15th. The company reported ($0.48) EPS for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.18). Roivant Sciences had a negative net margin of 2,110.83% and a negative return on equity of 68.61%. The company had revenue of $4.32 million for the quarter, compared to analyst estimates of $6.45 million. Research analysts predict that Roivant Sciences Ltd. will post -1.72 EPS for the current fiscal year.

Institutional Investors Weigh In On Roivant Sciences

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Tudor Investment Corp Et Al lifted its position in shares of Roivant Sciences by 483.9% during the 3rd quarter. Tudor Investment Corp Et Al now owns 354,099 shares of the company’s stock valued at $1,140,000 after acquiring an additional 293,459 shares during the last quarter. Renaissance Technologies LLC lifted its position in shares of Roivant Sciences by 169.8% during the 3rd quarter. Renaissance Technologies LLC now owns 227,400 shares of the company’s stock valued at $732,000 after acquiring an additional 143,100 shares during the last quarter. Two Seas Capital LP lifted its position in shares of Roivant Sciences by 71.6% during the 3rd quarter. Two Seas Capital LP now owns 5,869,690 shares of the company’s stock valued at $18,900,000 after acquiring an additional 2,449,854 shares during the last quarter. Teacher Retirement System of Texas raised its stake in Roivant Sciences by 97.4% during the 3rd quarter. Teacher Retirement System of Texas now owns 85,509 shares of the company’s stock valued at $275,000 after purchasing an additional 42,199 shares during the period. Finally, Daiwa Securities Group Inc. acquired a new stake in Roivant Sciences during the 3rd quarter valued at $35,000. Institutional investors and hedge funds own 51.44% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have recently commented on ROIV shares. JPMorgan Chase & Co. started coverage on Roivant Sciences in a report on Thursday, October 27th. They set an “overweight” rating and a $7.00 target price for the company. Citigroup boosted their price objective on Roivant Sciences from $9.00 to $10.00 and gave the stock a “buy” rating in a research report on Tuesday, August 16th. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $10.83.

Roivant Sciences Company Profile

(Get Rating)

Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia.

Further Reading

Insider Buying and Selling by Quarter for Roivant Sciences (NASDAQ:ROIV)

Receive News & Ratings for Roivant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roivant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.